F8 protein, human
(VMQMZMRVKUZKQL-UHFFFAOYSA-N)
Structure
- SMILES
- [Cu+]
- Molecular Formula:
- Cu+
- Molecular Weight:
- 63.546
- Log P:
- -0.0025
- Hydrogen Bond Acceptor:
- 0
- Hydrogen Bond Donor:
- 0
- TPSA:
- 0
- CAS Number(s):
- 17493-86-6; 139076-62-3
Synonym(s)
1.
F8 protein, human
2.
BAY 81-8973
3.
Bioclate
4.
F8B protein, human
5.
FVIII protein, human
6.
Hemofil
7.
Hemofil HM
8.
Hemofil M
9.
Hemophil
10.
Humate-P
11.
Kogenate
12.
Kogenate FS
13.
Kovaltry
14.
Monoclate
15.
Recombinate
16.
antihemophilic factor human
17.
coagulation factor VIII, human
18.
coagulation factor VIII, procoagulant component (hemophilia A) protein, human
19.
factor VIII, human
20.
octocog alfa
21.
xyntha
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 94 | US FAERS | |
| 2 | Factor VIII inhibition | FAERS: 84 Canada Vigilance: 9 | Canada Vigilance US FAERS | |
| 3 | Anti factor VIII antibody positive | FAERS: 78 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 4 | Product quality issue | FAERS: 38 | US FAERS | |
| 5 | Arthralgia | FAERS: 33 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 6 | Joint injury | FAERS: 26 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 7 | Joint swelling | FAERS: 24 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 8 | Limb injury | FAERS: 21 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 9 | Product use issue | FAERS: 21 | US FAERS | |
| 10 | Epistaxis | FAERS: 20 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 11 | Out of specification test results | FAERS: 20 | US FAERS | |
| 12 | Drug dose omission | FAERS: 18 | US FAERS | |
| 13 | Headache | FAERS: 14 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 14 | Pharmaceutical product complaint | FAERS: 14 | US FAERS | |
| 15 | Arthropathy | FAERS: 13 | US FAERS | |
| 16 | Pain | FAERS: 12 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 17 | Chest Pain | FAERS: 11 | US FAERS | |
| 18 | Medication Error | FAERS: 10 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 19 | Unevaluable event | FAERS: 10 | US FAERS | |
| 20 | Therapeutic product ineffective | FAERS: 9 | US FAERS | |
| 21 | Device related infection | FAERS: 8 | US FAERS | |
| 22 | Disease recurrence | FAERS: 8 | US FAERS | |
| 23 | Dizziness | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 24 | Nausea | FAERS: 8 | US FAERS | |
| 25 | Peripheral swelling | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 26 | Deep Vein Thrombosis | FAERS: 7 | US FAERS | |
| 27 | Inhibiting antibodies | FAERS: 7 | US FAERS | |
| 28 | Myocardial Infarction | FAERS: 7 | US FAERS | |
| 29 | No adverse event | FAERS: 7 | US FAERS | |
| 30 | Tooth Extraction | FAERS: 7 | US FAERS | |
| 31 | Back Pain | FAERS: 6 | US FAERS | |
| 32 | Drug effect incomplete | FAERS: 6 | US FAERS | |
| 33 | Hepatitis C antibody positive | FAERS: 6 | US FAERS | |
| 34 | Hypersensitivity | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 35 | Inappropriate schedule of drug administration | FAERS: 6 | US FAERS | |
| 36 | Incorrect dose administered | FAERS: 6 | US FAERS | |
| 37 | Intermittent Claudication | FAERS: 6 | US FAERS | |
| 38 | Nephrolithiasis | FAERS: 6 | US FAERS | |
| 39 | Urticaria | FAERS: 6 | US FAERS | |
| 40 | Abdominal Pain | FAERS: 5 | US FAERS | |
| 41 | Anti factor VIII antibody test | FAERS: 5 | US FAERS | |
| 42 | Asthenia | FAERS: 5 | US FAERS | |
| 43 | Central venous catheter removal | FAERS: 5 | US FAERS | |
| 44 | Hypotension | FAERS: 5 | US FAERS | |
| 45 | Musculoskeletal Pain | FAERS: 5 | US FAERS | |
| 46 | Pneumonia | FAERS: 5 | US FAERS | |
| 47 | Tachycardia | FAERS: 5 | US FAERS | |
| 48 | Wrong technique in drug usage process | FAERS: 5 | US FAERS | |
| 49 | Chills | FAERS: 4 | US FAERS | |
| 50 | Coagulation factor VIII level decreased | FAERS: 4 | US FAERS | |
| 51 | Endodontic procedure | FAERS: 4 | US FAERS | |
| 52 | General physical health deterioration | FAERS: 4 | US FAERS | |
| 53 | Hepatitis C | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 54 | Inhibiting antibodies positive | FAERS: 4 | US FAERS | |
| 55 | Malaise | FAERS: 4 | US FAERS | |
| 56 | Post-traumatic pain | FAERS: 4 | US FAERS | |
| 57 | Product availability issue | FAERS: 4 | US FAERS | |
| 58 | Product use in unapproved indication | FAERS: 4 | US FAERS | |
| 59 | Swelling | FAERS: 4 | US FAERS | |
| 60 | Tremor | FAERS: 4 | US FAERS | |
| 61 | Abasia | FAERS: 3 | US FAERS | |
| 62 | Adverse event | FAERS: 3 | US FAERS | |
| 63 | Antibody test positive | FAERS: 3 | US FAERS | |
| 64 | Asthma | FAERS: 3 | US FAERS | |
| 65 | Blood urine present | FAERS: 3 | US FAERS | |
| 66 | Cold sweat | FAERS: 3 | US FAERS | |
| 67 | Dysgeusia | FAERS: 3 | US FAERS | |
| 68 | Inappropriate schedule of product administration | FAERS: 3 | US FAERS | |
| 69 | Incorrect route of drug administration | FAERS: 3 | US FAERS | |
| 70 | Metrorrhagia | FAERS: 3 | US FAERS | |
| 71 | Muscle contusion | FAERS: 3 | US FAERS | |
| 72 | Muscle strain | FAERS: 3 | US FAERS | |
| 73 | Musculoskeletal discomfort | FAERS: 3 | US FAERS | |
| 74 | Nasopharyngitis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 75 | Product dose omission | FAERS: 3 | US FAERS | |
| 76 | Syringe issue | FAERS: 3 | US FAERS | |
| 77 | Therapeutic product cross-reactivity | FAERS: 3 | US FAERS | |
| 78 | Tonsillectomy | FAERS: 3 | US FAERS | |
| 79 | Abdominal discomfort | FAERS: 2 | US FAERS | |
| 80 | Accidental exposure to product | FAERS: 2 | US FAERS | |
| 81 | Adenoidectomy | FAERS: 2 | US FAERS | |
| 82 | Alopecia | FAERS: 2 | US FAERS | |
| 83 | Angina Pectoris | FAERS: 2 | US FAERS | |
| 84 | Aortic surgery | FAERS: 2 | US FAERS | |
| 85 | Appendicitis | FAERS: 2 | US FAERS | |
| 86 | Blood blister | FAERS: 2 | US FAERS | |
| 87 | Chest discomfort | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 88 | Cholelithiasis | FAERS: 2 | US FAERS | |
| 89 | Constipation | FAERS: 2 | US FAERS | |
| 90 | Diabetic Foot | FAERS: 2 | US FAERS | |
| 91 | Drug administration error | FAERS: 2 | US FAERS | |
| 92 | Drug clearance increased | FAERS: 2 | US FAERS | |
| 93 | Elbow deformity | FAERS: 2 | US FAERS | |
| 94 | Emergency Care | FAERS: 2 | US FAERS | |
| 95 | Extra dose administered | FAERS: 2 | US FAERS | |
| 96 | Fracture | FAERS: 2 | US FAERS | |
| 97 | Gastrointestinal Pain | FAERS: 2 | US FAERS | |
| 98 | Hip surgery | FAERS: 2 | US FAERS | |
| 99 | Incorrect drug administration duration | FAERS: 2 | US FAERS | |
| 100 | Incorrect product storage | FAERS: 2 | US FAERS | |
| 101 | Inflammation | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 102 | Initial insomnia | FAERS: 2 | US FAERS | |
| 103 | Injury associated with device | FAERS: 2 | US FAERS | |
| 104 | Intentional dose omission | FAERS: 2 | US FAERS | |
| 105 | Intentional product misuse | FAERS: 2 | US FAERS | |
| 106 | Intentional product use issue | FAERS: 2 | US FAERS | |
| 107 | Joint Range of Motion Decreased | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 108 | Laryngeal neoplasm | FAERS: 2 | US FAERS | |
| 109 | Maternal exposure during pregnancy | FAERS: 2 | US FAERS | |
| 110 | Metastatic Neoplasm | FAERS: 2 | US FAERS | |
| 111 | Musculoskeletal chest pain | FAERS: 2 | US FAERS | |
| 112 | Nodule | FAERS: 2 | US FAERS | |
| 113 | Orthodontic procedure | FAERS: 2 | US FAERS | |
| 114 | Osteorrhagia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 115 | Otitis Media | FAERS: 2 | US FAERS | |
| 116 | Product measured potency issue | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 117 | Product supply issue | FAERS: 2 | US FAERS | |
| 118 | Pruritus | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 119 | Restlessness | FAERS: 2 | US FAERS | |
| 120 | Spinal column injury | FAERS: 2 | US FAERS | |
| 121 | Suspected transmission of an infectious agent via product | FAERS: 2 | US FAERS | |
| 122 | Synovectomy | FAERS: 2 | US FAERS | |
| 123 | Thrombosis | FAERS: 2 | US FAERS | |
| 124 | Urinary tract infection | FAERS: 2 | US FAERS | |
| 125 | Wrong technique in product usage process | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 126 | colonoscopy | FAERS: 2 | US FAERS | |
| 127 | nervous system disorder | FAERS: 2 | US FAERS | |
| 128 | Accidental death | FAERS: 1 | US FAERS | |
| 129 | Accidental overdose | FAERS: 1 | US FAERS | |
| 130 | Accidental underdose | FAERS: 1 | US FAERS | |
| 131 | Agitation | FAERS: 1 | US FAERS | |
| 132 | Altered state of consciousness | FAERS: 1 | US FAERS | |
| 133 | Anger | FAERS: 1 | US FAERS | |
| 134 | Aortic aneurysm repair | FAERS: 1 | US FAERS | |
| 135 | Arthritis | FAERS: 1 | US FAERS | |
| 136 | Arthrodesis | FAERS: 1 | US FAERS | |
| 137 | Back disorder | FAERS: 1 | US FAERS | |
| 138 | Bronchitis | FAERS: 1 | US FAERS | |
| 139 | Bronchospasm | FAERS: 1 | US FAERS | |
| 140 | Burning sensation | FAERS: 1 | US FAERS | |
| 141 | Cardiac Flutter | FAERS: 1 | US FAERS | |
| 142 | Cataract | FAERS: 1 | US FAERS | |
| 143 | Cerebrovascular accident | FAERS: 1 | US FAERS | |
| 144 | Chemotherapy | FAERS: 1 | US FAERS | |
| 145 | Coagulation factor VIII level abnormal | FAERS: 1 | US FAERS | |
| 146 | Coagulation factor VIII level increased | FAERS: 1 | US FAERS | |
| 147 | Coronary Artery Disease | FAERS: 1 | US FAERS | |
| 148 | Crying | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 149 | Dehydration | FAERS: 1 | US FAERS | |
| 150 | Depressed Level of Consciousness | FAERS: 1 | US FAERS | |
| 151 | Device use issue | FAERS: 1 | US FAERS | |
| 152 | Disability | FAERS: 1 | US FAERS | |
| 153 | Discomfort | FAERS: 1 | US FAERS | |
| 154 | Drug Tolerance | FAERS: 1 | US FAERS | |
| 155 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 156 | Dry skin | FAERS: 1 | US FAERS | |
| 157 | Ear tube insertion | FAERS: 1 | US FAERS | |
| 158 | Ectopic Pregnancy | FAERS: 1 | US FAERS | |
| 159 | Epilepsy | FAERS: 1 | US FAERS | |
| 160 | Extravasation | FAERS: 1 | US FAERS | |
| 161 | Extremity necrosis | FAERS: 1 | US FAERS | |
| 162 | Factor VIII Deficiency | FAERS: 1 | US FAERS | |
| 163 | False positive laboratory result | FAERS: 1 | US FAERS | |
| 164 | Fatigue | FAERS: 1 | US FAERS | |
| 165 | Feeling Cold | FAERS: 1 | US FAERS | |
| 166 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 167 | Fibrin | FAERS: 1 | US FAERS | |
| 168 | Flatulence | FAERS: 1 | US FAERS | |
| 169 | Flushing | FAERS: 1 | US FAERS | |
| 170 | Hepatitis B DNA assay positive | FAERS: 1 | US FAERS | |
| 171 | Hepatitis B | FAERS: 1 | US FAERS | |
| 172 | Hernia | FAERS: 1 | US FAERS | |
| 173 | Human anti-mouse antibody positive | FAERS: 1 | US FAERS | |
| 174 | Hydrocephalus | FAERS: 1 | US FAERS | |
| 175 | Implantable defibrillator insertion | FAERS: 1 | US FAERS | |
| 176 | Increased tendency to bruise | FAERS: 1 | US FAERS | |
| 177 | Infection | FAERS: 1 | US FAERS | |
| 178 | Infusion site pain | FAERS: 1 | US FAERS | |
| 179 | Infusion site reaction | FAERS: 1 | US FAERS | |
| 180 | Injection site discomfort | FAERS: 1 | US FAERS | |
| 181 | Injection site extravasation | FAERS: 1 | US FAERS | |
| 182 | Injection site pain | FAERS: 1 | US FAERS | |
| 183 | Joint stiffness | FAERS: 1 | US FAERS | |
| 184 | Laceration | FAERS: 1 | US FAERS | |
| 185 | Ligament injury | FAERS: 1 | US FAERS | |
| 186 | Limb operation | FAERS: 1 | US FAERS | |
| 187 | Medical procedure | FAERS: 1 | US FAERS | |
| 188 | Medication dilution | FAERS: 1 | US FAERS | |
| 189 | Muscle tightness | FAERS: 1 | US FAERS | |
| 190 | Musculoskeletal stiffness | FAERS: 1 | US FAERS | |
| 191 | Near Drowning | FAERS: 1 | US FAERS | |
| 192 | Neck Pain | FAERS: 1 | US FAERS | |
| 193 | Night sweats | FAERS: 1 | US FAERS | |
| 194 | Nonspecific reaction | FAERS: 1 | US FAERS | |
| 195 | Obesity | FAERS: 1 | US FAERS | |
| 196 | Obstruction | FAERS: 1 | US FAERS | |
| 197 | Occult blood positive | FAERS: 1 | US FAERS | |
| 198 | Osteolysis | FAERS: 1 | US FAERS | |
| 199 | Osteoporosis | FAERS: 1 | US FAERS | |
| 200 | Pallor | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 201 | Pancreatic carcinoma | FAERS: 1 | US FAERS | |
| 202 | Paternal exposure timing unspecified | FAERS: 1 | US FAERS | |
| 203 | Plasmin inhibitor increased | FAERS: 1 | US FAERS | |
| 204 | Poor quality drug administered | FAERS: 1 | US FAERS | |
| 205 | Post procedural discharge | FAERS: 1 | US FAERS | |
| 206 | Post-Traumatic Headache | FAERS: 1 | US FAERS | |
| 207 | Procedural complication | FAERS: 1 | US FAERS | |
| 208 | Product contamination physical | FAERS: 1 | US FAERS | |
| 209 | Product lot number issue | FAERS: 1 | US FAERS | |
| 210 | Product storage error | FAERS: 1 | US FAERS | |
| 211 | Psoriasis | FAERS: 1 | US FAERS | |
| 212 | Purpura | FAERS: 1 | US FAERS | |
| 213 | Renal mass | FAERS: 1 | US FAERS | |
| 214 | Retinal Artery Occlusion | FAERS: 1 | US FAERS | |
| 215 | Splenic Rupture | FAERS: 1 | US FAERS | |
| 216 | Suture rupture | FAERS: 1 | US FAERS | |
| 217 | Syncope | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 218 | Synovial Cyst | FAERS: 1 | US FAERS | |
| 219 | Synovitis | FAERS: 1 | US FAERS | |
| 220 | Tachyphrenia | FAERS: 1 | US FAERS | |
| 221 | Therapeutic product effect incomplete | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 222 | Therapy change | FAERS: 1 | US FAERS | |
| 223 | Tongue biting | FAERS: 1 | US FAERS | |
| 224 | Tooth Loss | FAERS: 1 | US FAERS | |
| 225 | Vascular fragility | FAERS: 1 | US FAERS | |
| 226 | Vertigo | FAERS: 1 | US FAERS | |
| 227 | Visual Impairment | FAERS: 1 | US FAERS | |
| 228 | treatment failure | FAERS: 1 | US FAERS | |
| 229 | Anaphylactoid Reaction | Canada Vigilance: 1 | Canada Vigilance | |
| 230 | Anxiety | Canada Vigilance: 1 | Canada Vigilance | |
| 231 | Drug specific antibody | Canada Vigilance: 2 | Canada Vigilance | |
| 232 | Drug specific antibody present | Canada Vigilance: 2 | Canada Vigilance | |
| 233 | Eczema | Canada Vigilance: 1 | Canada Vigilance | |
| 234 | Erythema | Canada Vigilance: 1 | Canada Vigilance | |
| 235 | Inhibitory drug interaction | Canada Vigilance: 1 | Canada Vigilance | |
| 236 | Injection site bruising | Canada Vigilance: 1 | Canada Vigilance | |
| 237 | Injection site mass | Canada Vigilance: 1 | Canada Vigilance | |
| 238 | Limb mass | Canada Vigilance: 1 | Canada Vigilance | |
| 239 | Oropharyngeal pain | Canada Vigilance: 1 | Canada Vigilance | |
| 240 | Pain of skin | Canada Vigilance: 1 | Canada Vigilance | |
| 241 | Palpitations | Canada Vigilance: 1 | Canada Vigilance | |
| 242 | Rash erythematous | Canada Vigilance: 1 | Canada Vigilance | |
| 243 | Scab | Canada Vigilance: 2 | Canada Vigilance | |
| 244 | Secretion discharge | Canada Vigilance: 1 | Canada Vigilance | |
| 245 | Stress | Canada Vigilance: 1 | Canada Vigilance | |
| 246 | Toothache | Canada Vigilance: 1 | Canada Vigilance | |
| 247 | Vessel puncture site bruise | Canada Vigilance: 1 | Canada Vigilance | |
| 248 | skin abrasion | Canada Vigilance: 2 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.